All posts by imreal

Savoy Foundation Grants $150,000 to The New York Foundling Summer Camp Program for Inner-City Foster Care Children


Savoy Foundation Board of Directors Carl J. Morelli, Joseph Sciame, Frank J. Desiderio & John Laurent Gelati present grant to Melanie Hartzog, CEO of NY Foundling and Kirkley Strand, VP Development

Supporting The New York Foundling’s summer camp for inner-city youngsters fulfills the Savoy Foundation’s mission – Chivalry for Children’s Causes™

On July 18, 2022, the American Foundation of Savoy Orders presented a record grant of $150,000 to The New York Foundling’s Summer Camp Program for inner-city foster care children from funds raised from the Foundation’s 2021 Ballo di Savoia (Royal Savoy Ball) Winter Charity Gala.

More than 200 patrons, benefactors and guests gathered to support the Savoy Foundation’s 24th Annual white-tie dinner-dance on Saturday, December 11, 2021 in New York City at the Metropolitan Club. The Savoy Ball of New York continues a thousand-year tradition of goodwill and charitable giving under the patronage of the Royal House of Savoy. Their Royal Highnesses Prince Emmanuel Philibert of Savoy and Prince Dimitri of Yugoslavia were honored guests at the event that raised funds in support of the Savoy Foundation’s philanthropic mission – Chivalry for Children’s Causes – and the event’s primary beneficiary – The New York Foundling Summer Camp Program for inner city foster-care children.

Joseph Sciame, Savoy Foundation President and Carl J. Morelli, Foundation Chairman of the Board with Savoy Foundation Board members Frank J. Desiderio and John Laurent Gelati presented the grant to Melanie Hartzog, President and CEO of The New York Foundling and Kirkley Strand, Vice President of Development and Communications at The Foundling’s headquarters in New York City. Ms. Hartzog expressed her gratitude to the Savoy Foundation for the impact that the funds raised at the charity ball would have for more than 150 disadvantaged youths. The New York Foundling’s camp is in a new location in Sandyston, New Jersey, offering activities such as swimming, boating, fishing, zipline, rock climbing, ropes course, sports, arts, music, dance, and more.

Messrs. Carl J. Morelli Chairman and Joseph Sciame, President of the American Foundation of Savoy Orders, commented: “We are each overwhelmed by the generosity of our supporters who attended the December 2021 Savoy Ball of New York as well as so many others not able to be with us who donated to our GoFundMe efforts. We know our grant will make a major difference in the lives of young boys and girls who can enjoy the outdoors this summer at The New York Foundling’s summer camp.”

For more information on the philanthropic causes supported by the Savoy Foundation, please click here.

Businesses, individuals and organizations can donate here and find additional information about the Savoy Foundation Programs.

ABOUT THE SAVOY FOUNDATION AND THE AMERICAN DELEGATION OF SAVOY ORDERS

The American Delegation of Savoy Orders, which includes the United States of America, is among 35 delegations of the Savoy Orders located throughout Europe, the Americas and Japan. The Dynastic Orders of the Royal House of Savoy are among the oldest orders of chivalry in the world. Their origins and their principles, traditions and humanitarian goals, like those of the Royal House of Savoy that has the hereditary right to confer them, date back a thousand years. The American Delegation of Savoy Orders through its charitable arm, The American Foundation of Savoy Orders, Incorporated, contributes to humanitarian, hospitaller and charitable projects and initiatives in the United States and abroad, particularly in healthcare and hospice care, disaster relief, education programs and children’s causes.

The American Foundation of Savoy Orders, Incorporated, a 501(c) (3) charitable organization headquartered in New York City, has supported local, national, and international charities focusing on medical, educational, social assistance and humanitarian fields, including philanthropy for hospitals, relief agencies, children’s causes and hospice care for the poor, infirm and elderly. The Foundation whose current mission is “Chivalry for Children’s Causes” is a Non-Governmental Organization (NGO) in Roster Consultative Statues with the Economic and Social Council of the United Nations.

For more information on supporting the causes of the American Foundation of Savoy Orders, see below.

CONTACT:

Larissa Van Duser, Executive Director, American Foundation of Savoy Orders

amsavoy@aol.com, +1 212 972 0495

For more information, visit http://www.savoia.org

Share article on social media or email:

Pharmaceutical Process Validation Webinar on August 3, 2022


Pharmaceutical Process Validation

Best Practices for Success

An FDAnews Webinar

Wednesday, Aug. 3, 2022, 1:30 p.m.–3:00 p.m. EDT

https://wcg.swoogo.com/pharmaceutical-process-validation

The FDA is taking a tougher stance on deficiencies relating to current good manufacturing practices (cGMP). Drugmakers can avoid the inevitable warning letters and potential production stoppages and recalls when they shore up their process validation with the best practices in this webinar.

It will enable drugmakers to understand the importance of process validation throughout a product’s lifecycle, from concept, development, scale-up and production, through decommissioning.

Best of all, it will empower them to identify, control and ultimately reduce variability at every step. All while increasing homogeneity within and between lots and preventing FDA enforcement action.

John E. Lincoln, principal of J.E. Lincoln and Associates, will explain the takeaways from the FDA’s process validation guidance document and the must-have elements from ISO 14971:2019 (Application of Risk Management to Medical Devices) as a model for a pharmaceutical version and ICH Q9 – Quality Risk Management for hazard analysis, patient/product/process risk management and risk-based decisions. Mr. Lincoln will help attendees to integrate process validation essentials into their quality management system (QMS).

He’ll share how to develop, validate and refine processes to ensure their reliability, consistency and efficacy when attendees:


  • Understand the key points in the FDA’s process validation guidance document
  • Appreciate the value of their company when they put these principles into practice
  • Recognize the key process, equipment (production/test/lab), hardware and software, and QMS/21 CFR 11 verification and validation activities
  • Discover and use the lessons learned from sample test cases for installation qualification (IQ), operational qualification (OQ), performance qualification (PQ), Part 11 and cybersecurity requirements
  • Become familiar with the working definitions for verification, qualification, validation, commissioning/decommissioning and related terms so they can quickly and effectively communicate with both internal and external stakeholders
  • Get the gold-standard validation master plan and individual plans — with examples they can use with all their partners and stakeholders
  • Understand how to use verification and validation test report formats

The FDA is cracking down on process variation issues. If drugmakers want to ensure pharmaceutical process consistency, this webinar is essential.

Webinar Details

Pharmaceutical Process Validation

Best Practices for Success

An FDAnews Webinar

Wednesday, Aug. 3, 2022, 1:30 p.m.–3:00 p.m. EDT

https://wcg.swoogo.com/pharmaceutical-process-validation

Tuition:

$287

Easy Ways to Order:

Online: https://wcg.swoogo.com/pharmaceutical-process-validation

By phone: 888.838.5578 or 703.538.7600

About FDAnews:

FDAnews is the premier provider of domestic and international regulatory, legislative, and business news and information for executives in industries regulated by the US FDA and the European Medicines Agency. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books and conferences to stay in compliance with international standards and the FDA’s complex and ever-changing regulations.

Share article on social media or email:

Applying the Lessons of the Pandemic to Your Upcoming Trial Webinar on July 27, 2022


Applying the Lessons of the Pandemic to Your Upcoming Trial

A Free CenterWatch Webinar, Sponsored by PCM Trials

Wednesday, July 27, 2022, 11:00 a.m.-12:00 p.m. EDT

https://cwinfo.centerwatch.com/cw-web22727-applying-the-lessons-of-the-pandemic-to-your-upcoming-trial

Clinical trials are evolving at an unprecedented pace. And the push for rapid adoption of hybrid and decentralized clinical trials (DCT) is coming from all sides.

While the COVID-19 pandemic increased the number of hybrid and DCTs, the clear benefits mean there’s no going back. There’s a 93% increase in clinical trials with a virtual and/or decentralized component beginning in 2022, over those in 2020.

Traditional clinical trials are slower, more expensive and less efficient than DCTs and tend to limit participation by placing time and financial barriers on potential patients. Plus, they reduce diversity.

Ellen Weiss, PCM Trials’ vice president, in-home solutions, decentralized clinical trials, will explain the positive effects hybrid and DCT methods have on clinical trials now and into the future, helping attendees fully realize the advantages of trials, sharing:


  • Clinical trial-related lessons learned from the COVID-19 pandemic
  • The most-requested and most-used activities in home visit programs today
  • How to realize the benefits of decentralized clinical trials going forward
  • The role of home-based nursing in clinical trials
  • The timelines and processes a quality provider should deliver

Clinical trial professionals can improve trial enrollment, retention and diversity by integrating hybrid and DCT methods into their protocols.

Webinar Details:

Applying the Lessons of the Pandemic to Your Upcoming Trial

A Free CenterWatch Webinar, Sponsored by PCM Trials

Wednesday, July 27, 2022, 11:00 a.m.-12:00 p.m. EDT

https://cwinfo.centerwatch.com/cw-web22727-applying-the-lessons-of-the-pandemic-to-your-upcoming-trial

Tuition:

Free

Easy Ways to Order:

Online: https://cwinfo.centerwatch.com/cw-web22727-applying-the-lessons-of-the-pandemic-to-your-upcoming-trial

By phone: 888.838.5578 or 703.538.7600

About CenterWatch:

Founded in 1994, CenterWatch is a trusted source and global destination for clinical trials information for both professionals and patients. CenterWatch provides proprietary data and information analysis on clinical trials through a variety of newsletters, books, databases, and information services used by pharmaceutical and biotechnology companies, CROs, SMOs, and investigative sites involved in the management and conduct of clinical trials. As a pioneer in publishing clinical trials information, CenterWatch was the first Internet site to publish detailed information about active clinical trials that could be accessed by patients and their advocates.

Share article on social media or email:

Charles E. LaCombe’s newly released “At Rhythms Purest Form” is an enjoyable arrangement of poetic writings with compelling original art


News Image

“At Rhythms Purest Form”: a potent arrangement of spiritually charged original pieces. “At Rhythms Purest Form” is the creation of published author Charles E. LaCombe, a dedicated husband and father with a passion for travel, the arts, and the outdoors.

LaCombe shares, “I’m sure we can all agree that people drive you crazy sometimes. Though we all have similarities, we are by nature quite different. We inherit our own generational quirks, a mixing pot of emotions and hereditary habits.

“I can honestly say amid all our differences and shortcomings as human beings, I’ve had a certain love and care for people. It breaks my heart to see the pain in others’ lives. I’m sure we can also agree on the fact that there’s a lot of pain out there in the world. Darkness has a tight grip on our culture; it’s time we take up the light and say, “Not anymore.”

“This book is meant to bring light to this darkness that’s consuming our culture. It’s going to stir up some dust, make you curious, and maybe a little angry. Extinguish all resentment. Push it out of your heart. It only breeds more pain. Dig into the words; there are hidden meanings, within the hidden meanings, in these pages. We are meant to think and apply discipline and dedication to all we do. Don’t add to the laziness of our culture, be diligent and courageous. Push through the pain. No pain, no gain.

“For our light and momentary troubles are achieving for us an eternal glory that far outweighs them all. So we fix our eyes not on what is seen, but on what is unseen, since what is seen is temporary, but what is unseen is eternal. (2 Corinthians 4:17–18)

“The Creator’s message is all around us; that’s what we were made for, relationship to the Creator. Keep the communication line open constantly and endlessly, and be a witness to the many wonders. The Creator is ready to reveal the unseen, always and forever.”

Published by Christian Faith Publishing, Charles E. LaCombe’s new book will captivate and challenge readers as they take time for personal reflection.

LaCombe’s fine balance of vibrant imagery and reflective verse will charm and delight readers seeking a fresh opportunity for spiritual inspiration.

Consumers can purchase “At Rhythms Purest Form” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “At Rhythms Purest Form,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Glenda Crumbley’s newly released “From Chronic Pain to Purposeful Living” is an encouraging memoir that finds a determined woman beating the odds


News Image

“From Chronic Pain to Purposeful Living”: a helpful message of hope for those fighting against illness. “From Chronic Pain to Purposeful Living” is the creation of published author Glenda Crumbley, a dedicated mother of four and grandmother of seven who holds a master’s degree in public health.

Crumbley shares, “This book details the struggles of a woman who ultimately defied incurability and the medically unknown for the most part. After being diagnosed with Reflex Sympathetic Dystrophy (RSD) in 1999, Glenda fought to overcome bedridden and regain her place in society. Despite the nature of the incurable disease, Glenda realized without medical provision, she was in for a battle that could ultimately mean doom. In 2004 she began her journey by combing home remedies, trial and error, and prayer.

“However, instead of continually bowing to debilitating symptoms, Glenda had to exchange blows ‘the beast verses the remedy.’ Over time, she regained her sense of freedom. Glenda found that homeopathic remedies were the ‘life changers,’ so she has embarked on a mission to educate and encourage others to utilize health solutions that promotes quality of life.”

Published by Christian Faith Publishing, Glenda Crumbley’s new book will resonate with many who have found themselves trapped by an illness or injury.

Crumbley shares in hopes of helping others on their healing journey and to spread awareness of the potential within homeopathic remedies.

Consumers can purchase “From Chronic Pain to Purposeful Living” at traditional brick & mortar bookstores, or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “From Chronic Pain to Purposeful Living,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

Dental Care Alliance Extends a Warm Welcome to Bryn Mawr Dental Associates


“Bryn Mawr Dental Associates, Dr Paul Bookman, and team have been a beacon of high-quality dental care in northwest Philadelphia for more than two decades,” said Ryan Zeman, DCA Vice President, Business Development.

Bryn Mawr Dental Associates, situated in the northwest suburbs of Philadelphia, is the latest outstanding practice to affiliate with Dental Care Alliance (DCA). For more than 30 years, the team at Bryn Mawr Dental Associates has maintained a sterling reputation for providing the highest quality dental care, delivering a superior patient experience, and using the latest technology to meet the needs of patients. The practice has been recognized in Main Line Today’s “Top Dentist” issues annually since 2008.

The team utilizes the latest in technology and clinical innovations to create beautiful and healthy smiles for every patient that they serve. Bryn Mawr Dental Associates offers patients myriad services in a friendly and comfortable environment, including preventive, restorative, and cosmetic dentistry, as well as advanced services and technology such as home sleep tests for Obstructive Sleep Apnea, TMJ therapy, and CEREC® One visit restorations.

The doctors at Bryn Mawr Dental Associates maintain the highest levels of accreditation and pursue ongoing education to stay abreast of the latest trends in dentistry.

This affiliation continues the rapid growth and momentum for the organization and brings DCA’s footprint in the Philadelphia metro area to 30 allied practices, and DCA’s total footprint to over 380 allied practices across the US. “Bryn Mawr Dental Associates, Dr Paul Bookman, and team have been a beacon of high-quality dental care in northwest Philadelphia for more than two decades,” said Ryan Zeman, DCA Vice President, Business Development. “We are very excited about having their patient first culture and experience as part of the alliance.”

Dental Care Alliance’s mission is to advance the practice of dentistry by partnering with and supporting dental professionals to create a lifetime of healthy smiles. DCA currently supports over 380 allied practices with more than 775 dentists across 21 states. DCA’s allied practices represent all dental specialties and treat patients under more than 140 brand names.

#####

Share article on social media or email:

Shady Grove Fertility (SGF) Atlanta physicians recognized as 2022 Top Doctors for Infertility by Atlanta magazine


SGF Atlanta physicians, Drs. Brahma, McCarthy-Keith, Namnoum, and Libby recognized as Top Docs for Infertility by Atlanta magazine.

“As leaders in reproductive medicine, the SGF Atlanta physician team is committed to providing exceptional fertility care at a practice that remains at the forefront of cutting-edge reproductive technology. I am honored to be recognized by my peers and proud of our SGF Atlanta physician team.”

Shady Grove Fertility (SGF) Atlanta is proud to announce that physicians Pavna Brahma, M.D., Desireé McCarthy-Keith, M.D., M.P.H., Anne B. Namnoum, M.D., and Valerie Libby, M.D., have been named Atlanta magazine’s Top Docs for Infertility. This recognition is voted on by physician peers in various fields of medicine.

The doctors in this feature were selected by Professional Research Services (PRS), a firm based in Troy, Michigan, which conducted an online peer-review survey of all licensed physicians in the metro Atlanta area. Physicians were asked to nominate fellow physicians whom they deemed to be the best in their fields of practice. More than 10,000 votes were cast honoring excellence in all fields of medicine.

“As leaders in reproductive medicine, the SGF Atlanta physician team is committed to providing exceptional fertility care at a practice that remains at the forefront of cutting-edge reproductive technology,” shares Dr. McCarthy-Keith, medical director for SGF Atlanta. “I am honored to be recognized by my peers and proud of our SGF Atlanta physician team.”

SGF Atlanta provides a full range of diagnostic and treatment options complete with a premier IVF laboratory to help individuals and couples achieve their family-building goals. The regional practice offers four convenient offices in Alpharetta, Atlanta – Northside, Buckhead – Piedmont, and Marietta.

“I’m proud to be recognized by Atlanta magazine as a Top Doctor in the region, and I’m thankful my patients put their fertility care in my hands,” shares Dr. Brahma. “SGF Atlanta’s patient-centered approach to care aims to ensure fertility treatments are accessible and effective through innovative and evidence-based scientific approaches.”

SGF Atlanta proudly offers the Shared Risk 100% Refund Program. This exclusive program provides patients with the opportunity to pay a fixed amount for up to six fresh IVF or donor egg cycles and any subsequent frozen embryo transfers (FETs). Of the total Shared Risk 100% Refund Program participants, 82 percent take home a baby, and the rest receive a full refund to use for other family-building options.

“I am humbled to be recognized alongside my esteemed peers in our community for our commitment to providing compassionate, evidence-based fertility care,” shares Dr. Namnoum.

“It’s important for patients to know that they are part of the process, and I will be there for them every step of the journey,” shares Dr. Libby. “I’m honored to treat patients alongside these incredible physicians.”

For people struggling to conceive, it may be time to consult a fertility specialist. Contact the SGF New Patient Center at 1-888-761-1967 or complete a brief online request form to schedule a consult with an SGF physician. A physician consult is the first step toward pursuing a pregnancy with the help of SGF.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 100,000 babies born from 30+ years of continuous innovation and patient-centered fertility care. With 46 locations, including new locations in Texas, as well as throughout CO, FL, GA, MD, NY, PA, TX, VA, D.C., and Santiago, Chile, SGF offers patients in-person and virtual physician consults, delivers individualized care, accepts most insurance plans, and makes treatment affordable through innovative financial options, including 100% refund guarantees. SGF is among the founding partner practices of US Fertility, the largest physician-led partnership of top-tier fertility practices in the U.S. Call 1-888-761-1967 to schedule a new patient appointment or visit ShadyGroveFertility.com for more information.

Share article on social media or email:

Jump Technologies unveils Virtual Pick List to help hospitals manage physician preference card items and reduce waste


Source: Jump Technologies

By giving staff the option to work from their original pick list or to make changes based on actual usage data, Virtual Pick list gives hospitals a safe, easy way to protect valuable staff resources, reduce waste, and save money – all while solving the never-ending preference card dilemma.

Managing physician preference items is a daunting and time consuming task for nurses, because traditional preference cards are perpetually outdated. Fortunately, the new Virtual Pick List solution from Jump Technologies, a leading hospital supply chain solutions and analytics company, gives nurses and supply chain staff the power to streamline physician preference items – once and for all.

Virtual Pick List uses patent-pending machine learning technology to analyze case data from a hospital’s electronic medical record system and identify changes to the case pick list that accurately reflect what physicians use during procedures. The Virtual Pick List is printed prior to a case. Suggested changes are clearly marked, showing items that should not be picked, changes to open and hold quantities, as well as items that should be picked that are not currently on the preference card. This allows the person picking the case to follow the items and quantities suggested by Virtual Pick List, or to pick items as per the original pick ticket.

“Choice is good, and our Virtual Pick List solution gives nursing staff choices that are backed by the power of data and machine learning,” said John Freund, CEO, Jump Technologies. “By giving staff the option to work from their original pick list or to make changes based on actual usage data, Virtual Pick list gives hospitals a safe, easy way to protect valuable staff resources, reduce waste, and save money – all while solving the never-ending preference card dilemma.”

The machine learning algorithm that powers the Virtual Pick List identifies items that were actually used in a given case, which items were pulled but not used, and items that were requested during a procedure but that weren’t on the original pick list. This data is constantly monitored, allowing the Virtual Pick List system to make suggestions to the pick list as information changes over time. Virtual Pick Lists allow hospitals to:


  • Save money by eliminating waste that is caused when items are picked and opened for a case, but not used.
  • Help reduce staff stress and fatigue by freeing up valuable staff time, as nurses and supply chain staff pick only items that are actually used during a case.
  • Eliminate the time and costs associated with preference card clean up by establishing a constant preference card monitoring system that recommends changes, when appropriate.

The Virtual Pick List is available as a standalone solution that joins the JumpStock inventory management platform and Case Companion for the OR, offering a complete dock-to-patient inventory management platform for hospitals. To see a demonstration of the Virtual Pick List and how Jump Technologies can help hospitals and health systems streamline physician preference cards, visit http://www.jumptech.com/virtualpicklist.

###

About Jump Technologies

Headquartered in Eagan, MN, Jump Technologies creates safe, simple, and cost-effective solutions that help hospitals reduce stock outs, overordering, and waste, while increasing inventory turns and improving billing accuracy across a facility or system. The company’s JumpStock solution facilitates data-driven decision making that allows hospitals to save time, free up cash, and improve nurse satisfaction with supply chain. To learn more, visit http://www.jumptech.com or call (888) 373-7226. Follow Jump Technologies on LinkedIn and Twitter @JumpTechNews.

Media contact: Barbara Tabor, APR / (651) 230-9192 / barbara@taborpr.com

Share article on social media or email:



Cosán and Genomind Partner to Help Prevent Adverse Prescription Drug Events for Older Adults


Cosán and Genomind Logos

Cosán and Genomind Partner to Help Prevent Adverse Prescription Drug Events for Older Adults

Genomind’s analytic capabilities will provide Cosán with risk stratification insights, enabling Cosán clinicians to target individuals that are most likely to benefit from medication reviews and pharmacogenetic (PGx) testing.

Cosán, a provider of technology-driven preventative care services for older adults and the physicians that support them, and Genomind, a leading precision healthcare company, have partnered to fill an existing gap in aging adult care management by providing Cosán’s network of physicians with Genomind’s integrated precision medication management platform. The platform will provide insights that will help Cosán to achieve the best outcomes for its patient population, prevent adverse drug events and reduce avoidable costs of medication mismanagement.

With over 40% of U.S. adults 65 years of age and older taking five or more prescription medicines, aging populations are at high-risk for adverse drug events. Through this partnership, Genomind’s analytic capabilities will provide Cosán with risk stratification insights, enabling Cosán clinicians to target individuals that are most likely to benefit from medication reviews and pharmacogenetic (PGx) testing, also known as drug-gene testing. Genomind’s PGx test adds a layer of precision medicine that leverages genetics to help providers select appropriate medications and dosing. Equipped with advanced pharmacogenetic screening, clinical concierge services and access to expert pharmacists, Cosán’s care teams can then incorporate individualized insights into each patient’s chronic care management plan so medications are administered safely.

“This partnership brings a new level of pharmacy and genetic expertise to thousands of providers and the patients they support, marking yet another stride in the delivery of effective preventative care management services,” said David Hunt, Founder & President at Cosán. “These unique drug analytic and genetic testing capabilities provide Cosán’s network of physicians and care coordinators with another tool designed to help eliminate avoidable drug risks and improve overall care quality for vulnerable patients receiving care from their homes.”

According to the CDC, adverse drug events cause approximately 1.3 million emergency department visits each year, and older adults are nearly seven times more likely to end up hospitalized after such events than younger persons. Many of these adverse events are caused by just a few drugs. This new platform will help physicians develop personalized therapeutic approaches for patients based on their individual genetic makeup and is designed to improve patient and physician satisfaction and reduce medical expenses. With the recent expansions by Medicare to cover PGx testing in certain circumstances, this population is particularly suited to dramatically benefit from this platform.

“The prevalence and cost of medication mismanagement is unacceptable, costing thousands of lives and billions of dollars annually. We’re thrilled to join Cosán in helping to improve care management for older adults, who are at high risk for these adverse drug events,” said Cynthia Kilroy, Co-CEO, Genomind.

The Cosán/Genomind platform is currently in the pilot testing stage and is expected to become widely implemented this year.

About Cosán Group

Cosán Group, established in 2015, is an industry-leading healthcare organization creating new pathways to modern aging with technology-driven preventative care services, offering concierge home care for older adults. Early market exposure in the delivery of technology and services to support the Chronic Care Management (CCM) program, and Behavioral Health Integration (BHI) programs with Remote Patient Monitoring (RPM) has propelled Cosán to deliver a practiced and patient-centric approach to remote care coordination. Visit our website: http://www.cosangroup.com

Media Contacts

Clinical inquiries: Desiree Martin – Vice President-Clinical Operations

desiree.martin@cosangroup.com

Business Inquiries: Michael Knipper – Vice President, Sales & Strategic Partnerships

michael.knipper@cosangroup.com

Press: Garth Cabral – Director of Marketing & Brand Management

garth.cabral@cosangroup.com

About Genomind

Genomind is a leading precision health company focused on optimizing the treatment experience for individuals and healthcare providers through actionable genetic insights and innovative health technology. Genomind’s platform integrates precision health technology and pharmacogenetic testing on an individual and population level beyond mental health. Built on the foundation of compassionate care and clinical expertise, Genomind is empowering a more targeted and personalized approach to medication management and supporting providers in a new standard of care.

Learn more at http://www.genomind.com.

Media Contacts

Clinical inquiries: David Krause, MD – dkrause@genomind.com

Business inquiries: Cynthia Kilroy – ckilroy@genomind.com

Share article on social media or email:

ClinOne to Showcase Adaptive Experiences in Cancer Studies, Including eConsent, Trial Awareness, and Patient Ride at Clinical Trials in Oncology East Coast Conference


“We’re excited about the power of adaptive experiences in Oncology trials; they make multiple workflows available, whether using technology or not, so patients can decide how to participate in a way that doesn’t get in the way of their daily lives.” – ClinOne CEO Andrea Valente

ClinOne, the true single platform for adaptive experiences in clinical trials, will showcase the value of technology for cancer studies – including eConsent, trial awareness, and patient ride – at Clinical Trials in Oncology East Coast, July 19-20, 2022 at the Boston Marriott Newton.

While the ClinOne platform spans therapeutic areas, it is especially beneficial for studies that face recruitment and awareness, consent and enrolment, and patient retention and compliance challenges:

  • Recruitment and awareness – In hard-to-recruit patient populations, raising awareness of a clinical trial with the local HCP community can generate peer-to-peer conversations that make it easier to connect people to the study, reaching huge and diverse patient pools through trusted care team relationships.
  • Enrolment and consent – Cancer studies have notoriously complex consent processes with multiple ICF types and frequent amendments that place a significant burden not only on patients but also site staff to manage version control and re-consent status.
  • Patient retention and compliance – Keeping patients engaged in multi-year studies in the face of the many other priorities they are focused on outside of the trial can be supported by patient ride, background medication adherence, virtual visits when appropriate, and more.

“Oncology studies – and more importantly the people who participate in and run them – have specific challenges and requirements that demand and deserve special attention,” said Andrea Valente (LinkedIn), CEO of ClinOne. “The lives of cancer patients are very full and often complex, and they know best what will work for them at any given time. We are excited about the power of adaptive experiences because they make multiple workflows available, whether using technology or not, so they can make the right decision on how to participate in a way that doesn’t get in the way of their daily lives.”

Featuring solutions for trial awareness, eConsent, and patient ride, the ClinOne platform helps oncology patients and families connect with their research site and take control of their trial experience. The platform also features a self-dosing compliance manager, and eDiaries for QOL questionnaires. Additionally, ClinOne offers the industry’s fastest deployment, often in less than 4 weeks so participants can experience benefits faster than ever.

Learn how ClinOne will help you connect, inform, and empower patients to get the results you need and the experience patients deserve at http://www.clinone.com.

About ClinOne

ClinOne provides adaptive experiences for participants in clinical trials. By offering choice to patients, caregivers, and site staff, our technology makes it easier to stay active, compliant, and comfortable in a trial – thereby expanding enrollment access, reducing drop-out rate, and shortening conduct timelines. Our true single platform features solutions for local HCP trial awareness, remote and on-site eConsent, Uber Health, medication adherence, and a DCT portal. ClinOne stands alone with the industry’s fastest implementation (average 2-4 weeks), cost-efficient scale, and seamless API integrations for complex therapeutic areas such as Oncology, CNS, and Rare Disease in over 60 languages. To learn why more than 55 sponsors and CROs trust ClinOne in 100+ currently active studies to connect, inform, and empower participants to take control of their clinical trial experience, begin a conversation with our experts at http://www.clinone.com.

Share article on social media or email: